Anaeropharma strives for creating innovative therapies for solid cancer and other hypoxic lesions related diseases like ischemia based on our core platform technology, i-DPS. We have established several development programs including APS001F to target solid tumor under phase I/II clinical trial, and anticancer drugs in the area of immuno-oncology and an anti-ischemic drug under preclinical development. Our ongoing preclinical and clinical programs build value of proof of concept for the platform technology to create innovative new drug candidates.